High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma

Key Points Autoimmune neutropenia is a rare side effect of nivolumab which may respond to antibody-based therapies. Nivolumab can lead to durable complete remission in primary mediastinal B-cell lymphoma refractory to multiple lines of therapy.